Yahoo Finance

GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

Innovative multi-biomarker blood test based on GENFIT’S NIS4™ technology is specifically designed to identify patients with at-risk non-alcoholic steatohepatitis (NASH) LabCorp to commercialize the ...
Business Wire

LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider

LabCorp will purchase Envigo’s nonclinical contract research services business, expanding the global reach and capabilities of Covance’s nonclinical drug development business Envigo’s research models ...
Business Wire

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)

Multi-Biomarker Test Will Provide the Clinical Research Community with a Non-Invasive Tool to Identify and Monitor Patients with NASH and Significant Fibrosis LILLE, France & CAMBRIDGE, Mass. & ...
Yahoo Finance

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic SteatoHepatitis (NASH)

LILLE, FRANCE; CAMBRIDGE, MASS.; AND BURLINGTON, N.C. - January 3, 2019 - LabCorp® (LH), a leading global life sciences company, and GENFIT (GNFT.NX), a late-stage biopharmaceutical company dedicated ...
Finanznachrichten

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)

Multi-Biomarker Test Will Provide the Clinical Research Community with a Non-Invasive Tool to Identify and Monitor Patients with NASH and Significant Fibrosis LabCorp (NYSE: LH), a leading global life ...